Name: Latest research reports of Piramal Pharma Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Piramal Pharma Ltd.
Rating: 5
Author: Motilal Oswal

CDMO segment drives earnings

Buy: Piramal Pharma Ltd.

Target

Motilal Oswal

Piramal Pharma (PIRPHARM) delivered better-than-expected operational
performance for the quarter. Compared to adj. loss of INR800m in FY23,
PIRPHARM’s effort has led to adj. PAT of INR560m for FY24.